Deerfield Management Company, L.P. (Series C) Silverback Therapeutics, Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $4.84 Billion
- Q1 2024
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Silverback Therapeutics, Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 11,077,927 shares of SBTX stock, worth $0. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,077,927
Previous 11,077,927
-0.0%
Holding current value
$0
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding SBTX
# of Institutions
117Shares Held
47.9MCall Options Held
442KPut Options Held
42K-
Orbimed Advisors LLC San Diego, CA9.24MShares$00.0% of portfolio
-
Sr One Capital Management, LP4.01MShares$00.0% of portfolio
-
Franklin Resources Inc San Mateo, CA2.95MShares$00.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.89MShares$00.0% of portfolio
-
Black Rock Inc. New York, NY2.66MShares$00.0% of portfolio
About Silverback Therapeutics, Inc.
- Ticker SBTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,473,800
- Description
- Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverba...